SEC Filing Summary: Harvard Bioscience, Inc. (HBIO)
Business Context and Reporting Period
This Form 8-K Current Report, dated August 8, 2024, announces the financial results for Harvard Bioscience, Inc. for the three months ended June 30, 2024. The filing serves to incorporate by reference a press release (Exhibit 99.1) detailing these results and a related conference call.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) and are not explicitly stated in the body of this 8-K document.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The document solely references the announcement of results without providing comparative data.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not described in this filing. The report indicates that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for the quarter ended June 30, 2024.
- Verify year-over-year growth rates and margin trends in the referenced press release.
- Check the conference call transcript for management's updated guidance and commentary on market conditions.
- Confirm the status of the company's liquidity and debt obligations as detailed in the full financial statements.